Lv42
704 积分 2025-07-30 加入
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
19天前
已完结
Complete Regression of Hepatoblastoma after Interleukin-15- and Interleukin-21-Coexpressing CAR T-Cell Therapy
2个月前
已完结
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial
2个月前
已完结
The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer
2个月前
已完结
Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2个月前
已关闭
Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer
2个月前
已完结
Claudin proteins as emerging therapeutic targets for solid tumours
2个月前
已完结
The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer
2个月前
已完结
Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer
2个月前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
2个月前
已完结